New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
06:03 EDTVNDAVanda pullback a buying opportunity, says Piper Jaffray
Piper Jaffray recommends using the post-earnings pullback in shares of Vanda Pharmaceuticals as a buying opportunity. Piper says Hetlioz is launching well and that it sees no reason to back off its bullish stance or $25 price target. The firm reiterates an Overweight rating on the name.
News For VNDA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
07:47 EDTVNDAVanda receives positive CHMP opinion for Hetlioz for sleeping disorder in the EU
Subscribe for More Information
April 20, 2015
08:12 EDTVNDAVanda names Tom Gibbs as SVP and Chief Commercial OfficerBristol-Myers
Subscribe for More Information
April 13, 2015
17:48 EDTVNDAVanda announces Feb. 29, 2016 trial date for Fanapt patent cases
Vanda Pharmaceuticals announced a February 29, 2016 trial date for two pending cases against Roxane Laboratories regarding Roxane's submission of an ANDA to obtain approval to make and sell generic Fanapt. The two cases have been consolidated by agreement of the parties and are scheduled to be tried together in a four-day bench trial beginning on February 29, 2016. In C.A. No. 14-757-GMS, Vanda is asserting U.S. Patent No. 8,586,610 ('610 patent), covering methods of treating schizophrenia by administering Fanapt to certain patients, while in C.A. No. 13-1973-GMS, Vanda is asserting the U.S. composition of matter patent for Fanapt, U.S. Patent No. RE39,198. Both patents are listed in the FDA publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The '610 patent expires November 2027 and the RE'198 patent expires November 2016.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use